Businesses, suppliers, leaders, and professionals across the mining spectrum are cordially invited to attend MiningNews Select 2024 at the Sydney Masonic Centre on March 18-19, 2024. This premier event offers companies engaged in gold and other mining resources an unparalleled opportunity to leverage the expansive reach, knowledge, and networking prospects it provides.

Investors will have the chance to engage directly with mining companies in intimate one-to-one discussions, exploring a plethora of potential investment avenues. With over 400 investor meetings, 40+ influential speakers, and a gathering of 250+ private and institutional investors, the event promises over 15 hours of robust networking opportunities.

A notable lineup of 30+ aspiring miners and companies will present their top-rated projects and services to an audience of over 150 institutional and retail investors. Backed by an expert panel of industry veterans, mining companies will have ample support to foster connections, forge partnerships, and cultivate business ties through personalized meetings and discussions.

The mining companies showcased at the MiningNews event are meticulously selected by the MiningNews team, renowned for their rigorous research and analysis. This ensures a curated list of companies boasting outstanding talents and prospects, offering investors a gateway to discovering promising mining ventures with a bright future.

To facilitate meaningful interactions, event organizers have arranged branded booths equipped with screens, enabling mining companies to host focused investor meetings. With over 35 years of experience closely intertwined with the Australian mining sector and investment markets, the team behind MiningNews orchestrates these well-curated events with precision.

Their research team, armed with 24 different metrics, has distilled them into 13 key metrics to identify the top mining projects. By providing investors with clear insights into market drivers and offering mining companies an optimal platform to showcase their capabilities, MiningNews empowers stakeholders to navigate the industry landscape with confidence and clarity.

To learn more, please visit https://ibn.fm/N5brp

• “In the dynamic world of investments, electric boat stocks are gaining momentum,” reports InvestorPlace
• The article calls Vision Marine a key player in the electric boat stocks market
• VMAR’s recent partnerships, market expansion and production enhancements point to potential growth and innovation

As investors pay increasing attention to potential involvement in clean, green-energy companies, the idea of sustainability is becoming more of a priority in sectors across the board. Vision Marine Technologies (NASDAQ: VMAR), a global leader and innovator in the performance electric recreational boating industry, is capturing attention and was recently spotlighted in an InvestorPlace article titled “Three Electric Boat Stocks That Will Sail Higher by 2024” (https://ibn.fm/ZFu5W).

“In the dynamic world of investments, electric boat stocks are gaining momentum,” the article stated. “These ‘e-boat stocks’ blend innovation with eco-sustainability. They mark a significant shift in the maritime sector. Traditionally high in emissions, this industry is now embracing green technology.

“Electric boat stocks are not just eco-friendly; they promise strong growth potential,” the article continued. “As renewable energy gains traction, maritime transport is also transforming. Electric propulsion and advanced batteries are key. They position e-boats as leaders in this emerging market. Investing in e-boat stocks goes beyond finances; it’s an eco-commitment. These companies are reducing the maritime industry’s carbon footprint. They offer sustainable, cost-effective solutions. With stricter environmental regulations, the shift to electric boats is inevitable.”

The article calls Vision Marine a key player in the electric boat stocks market, noting that despite some challenges, the company’s recent “strategic moves suggest a promising future in the electric boating sector.” The article noted VMAR’s partnership with 4ocean, along with its expansion into the pontoon market, which shows a “strategic diversification,” a move that InvestorPlace says “could be a game-changer for Vision Marine, showcasing its adaptability and innovation in the market.”

The article observes that “the company’s acquisition of industrial tooling to enhance its production capabilities is a strategic step. It aims to support the production of over 10,000 battery packs annually, meeting the increasing demand for electric marine propulsion systems.

Despite financial headwinds, Vision Marine Technologies is positioning itself as a forward-thinking leader in the electric boat industry. Vision Marine’s commitment to sustainability and market diversification might steer it towards a more prosperous future despite current challenges.”

As the global leader in the electric recreational boating industry serving both OEMs and consumers, Vision Marine is pioneering the clean-energy transition on the water by selling 100% electric boats, outboard motors and technology throughout the marine industry. In addition, the company strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power.

For more information, visit the company’s website at www.VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Research forecasts global medical marijuana space will see CAGR of 22.32% over the next decade
• Several key factors contribute to double-digit growth
• MedCana has assembled a team of pharmaceutical scientists who are some of the world’s most respected chemists

Recent forecasts for the global medical marijuana sector indicate significant growth, a trend that Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is paying close attention to. A global infrastructure and holding company in the cannabis industry, MedCana is on a mission to become the world’s premier resource for pharmaceutical cannabis products.

The recent ResarchAndMarket.com article reported that the global medical marijuana market size was estimated to be $16.88 billion in 2023 and is expected to reach at $154.83 billion by 2034, with a CAGR of 22.32% during the 2024–2034 forecast period (https://ibn.fm/ZyJ3m). “Growing awareness regarding various therapeutic applications of the marijuana, a surge in permitting the usage of medical marijuana, increasing adoption of cannabis in therapeutic applications, rising research and development activities, growing prevalence of chronic diseases, and increase in acquisition of market players for the manufacturing of advanced medical products are some of the key factors boosting the market growth,” the article stated.

“The North America region is anticipated for the highest revenue share during the forecast period, owing to the surge in cannabis legalization and increasing product launches by major market players,” the article continued. “Increased launch of advanced medical products is predicted to boost the market growth during the forecast period. Medical marijuana, also known as medical cannabis, is a marijuana plant extract utilized to alleviate symptoms, illnesses, and various health conditions. Numerous North American states have relaxed laws regarding cannabis use, both for medical and recreational purposes.”

The article also noted that many other countries worldwide are following North America’s lead by legalizing cannabis. “The increasing trend of cannabis decriminalization is expected to significantly boost the development and launch of medical marijuana,” the report concluded.

With this backdrop of growing awareness and acceptance of medical cannabis, MedCana is well positioned to become an industry leader. The company has assembled a team of pharmaceutical scientists that are some of the most respected chemists in the world (https://ibn.fm/ClWNH). These experts work closely with MedCana partners and customers to create premium pharmaceutical-grade cannabis extracts that will meet the growing worldwide demand for high-quality products.

MedCana has established five companies focused on pharmaceutical cannabis production, as well as a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company.

The company’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts globally.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

Businesses, leaders, enthusiasts, and service providers of the cannabis spectrum are all invited to the NECANN Boston Convention, the 2nd largest B2B cannabis industry event across the globe. Since its 70th booth convention back in 2015, NECANN has come a long way. This year’s convention will feature over 350 exhibitors, several workshops, five full programming tracks, and a day-long financial/investor summit. The age limit to attend the conference is 18+ unless accompanied by a guardian.

The NECANN event is a phenomenal business platform attracting the New England cannabis trading community and other visitors. Influential cannabis industry leaders will be at the event, offering critical knowledge and developing industry insights. Experts will share strategies, ideas, and trends in the cannabis industry, while attendees harness the latest growth opportunities the platform offers. Enjoy unique experiences of networking and communication among peers, investors, and industry leaders.

Discussions will cover a number of important topics ranging from 280 changes and cannabis exit strategies, to insights from experts on sourcing diverse products, exploring funding through social equity programs, building a meaningful business network, and other subjects. Industry leaders will also explain the importance of community involvement, and how data analytics can impact business performance. In addition, the panel will talk about illicit cannabis operators based on recent numbers provided to them.

The NECANN  Boston Convention offers numerous business and growth avenues to the cannabis community. You will learn the latest industry trends and technologies to stay competitive in the fast-growing cannabis industry.

Due to popular demand, a THIRD exhibit hall, along with more programming and workshops, will be added.

To learn more, visit https://ibn.fm/fAdy7

• Mortgage services company Mr. Cooper reported a breach in stolen data on approximately 15 million customers concerning names, addresses, social security numbers, account numbers, date of birth, and phone numbers
• Sekur CEO Alain Ghiai hypothesizes that the breach was likely due to an email account within Mr. Cooper
• Sekur’s services include SekurMail(R), with SekurSend/SekurReply, SekurVPN(R), and SekurMessenger(R) utilizing the company’s wholly-owned Swiss-hosted servers

New to the Street’s most recent “Sekur Privacy & Sekur Security – The Weekly Hack” segment between TV host and multi-media journalist Ana Berry and internationally acclaimed internet privacy expert and Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GDT0) CEO Alain Ghiai discusses the recent data breach of Mr. Cooper, one of the largest mortgage lenders (https://ibn.fm/Vp9SA).

Mr. Cooper, a Texas based company in the mortgage services industry, reported a breach in stolen data involving approximately 15 million customers – including names, addresses, social security numbers, account numbers, date of birth, and phone numbers. The mortgage lender sent letters to customers offering free monitoring services to help notify clients if someone is using their stolen data in the future (https://ibn.fm/BJR61).

Mr. Ghiai, CEO of Sekur, believes the breach occurred from an email account within Mr. Cooper. He said 91% of cyber issues stem from emails, especially those on Big Tech platforms. Many large corporations use Big Tech platforms for their IT needs, with limited countermeasure cybersecurity features.

To avoid cyberhackers’ attempts at breaching data, Sekur, a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, makes it possible to send information through the most secure methods possible with a Sekur subscription. SekurMail(R), with SekurSend/SekurReply options, sends a link to a recipient to open an email in a closed-loop encrypted military platform. The service protects both subscriber and recipient, even if the recipient is not a Sekur subscriber.

Paired with the company’s SekurVPN(R), subscribers gain an additional layer of encryption that protects the IP addresses and website traffic information. SekurVPN creates a secure, encrypted connection between client’s devices and the internet, giving safe access to the web by routing connections through the company’s wholly-owned Swiss servers. All data sent and received is hidden from prying eyes, including the client’s Internet Service Provider (“ISP”), potential hackers, government surveillance agencies, and more.

Sekur also offers SekurMessenger(R), a Swiss-hosted private and secure private chat, self-deleting chat, voice recording, and file transfer via any mobile device, tablet, or desktop computer. The app is designed to provide military-grade encryption and privacy by ensuring that only the sender and intended recipient can read the messages exchanged.

Sekur’s servers are wholly owned, and the company never sells data, never uses phone numbers, has no third-party cloud applications, and never tracks web traffic. All user data is protected by the Swiss Federal Data Protection Act and the Swiss Federal Data Protection Ordinance, which offers some of the strongest privacy protection in the world for both individuals and organizations.

Monthly subscription amounts range from $12-$20, with business customers having slightly higher pricing due to business email domain migration. Mr. Ghiai offers New to the Street viewers a 15% discount on all Sekur services for up to five years with PROMO CODE: PRIVACY.

New episodes of “Sekur Privacy & Sekur Security – Weekly Hack” can be found each week on the New to the Street YouTube channel (https://ibn.fm/Gf7Ll).

For more information, visit the company’s website at www.SekurPrivateData.com or the company’s product site at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Artificial Intelligence is expected to both, drive global energy consumption whilst simultaneously, increasing the efficiency of global power usage
• Turbo Energy is seeking to harness artificial intelligence in the manufacture and development of their residential energy solutions, which allow households to capture and store solar energy
• The Company has recently entered into an agreement with Solar360, the energy-focused subsidiary of Repsol and Telefonica, in a move to dramatically increase their distribution footprint

The growing demands of artificial intelligence (“AI”) are set to drive a sharp increase in data center storage capacity, with the latter expected to grow from 10.1 zettabytes (“ZB”) in 2023 to 21.0 ZB in 2027, a five-year compound annual growth rate of 18.5%. Whilst this increased storage capacity is set to drive a huge proliferation in data centers, it will similarly drive a significant surge in energy usage, with data centers forecast to consume over 1% of global electricity in the coming years (https://ibn.fm/G8Vaz). Nonetheless, AI is simultaneously being harnessed to reduce energy expenditure – Google recently revealed that its AI-driven approach to data center cooling had led to a reduction of about 40 percent in energy use, the equivalent to taking 64,000 cars off the road annually.

The use of artificial intelligence is gaining increased relevance in terms of tackling carbon emissions, with recent analysis by global consultants McKinsey suggesting that AI-enhanced manufacturing could reduce global greenhouse gas emissions by 10-20 percent. Similarly, and within the energy sector, the adoption of AI technologies – which range from smart thermostats to more efficient solar panels – are forecast to drive a significant reduction in utility emissions in the coming years.

Turbo Energy (NASDAQ: TURB), a designer, developer and manufacturer of photovoltaic energy generation, management, and storage equipment has sought to capitalize on this growing trend. The Company’s ‘Sunbox Home’ system encompasses an all-in-one AI-powered energy storage solution, designed to assist households in managing their power consumption. Directly linked to a household’s solar panel generation unit, the Sunbox system allows users to choose between settings including ‘maximum consumption’ or ‘maximum savings’, to conserve a portion of its energy reserves in the event of unexpected electricity blackouts or rather, sell excess power back onto the grid. The groundbreaking energy storage system additionally boasts the capacity to track weather forecasts, thus ensuring its batteries are fully charged in the event of a storm (https://ibn.fm/M1cdr).

It is this very focus on renewable energy systems and relentless dedication towards AI-driven technological innovation that Turbo Energy’s CEO Mariano Soria credits as the driver for Turbo Energy’s recent tie-up with Repsol and Telefonica’s energy-oriented subsidiary, Solar360.

“Turbo Energy’s Artificial Intelligence and optimization system is the best on the market,” stated Soria in a recent interview. “Two years ago, we began working on the development of software linked to Artificial Intelligence. The goal was for storage to be smart, that could not only serve the purpose, but save money directly from the end user’s pocket. [In addition to having] the capacity to offer the end customer the best solution in economic savings [our] software is the basis for the continued development of the company [as well as giving us] the ability to incorporate other elements in the future]. We envision the ability to make use of it, not only for individuals but for communities such as energy communities or virtual power plants.”

The global AI in energy market size – which encompasses the deployment of AI technologies towards optimizing energy consumption and reducing costs across buildings, industrial processes, and power grides – is forecast to grow from a value of $4 billion in 2021 to an annual market size of $19.8 billion by 2031, equivalent to a CAGR of 17.4% over the course of the decade. With a focus on technological innovation and now, a growing distribution footprint across Europe and the world, Turbo Energy looks well placed to capitalize on the opportunity at hand.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial
• This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients
• Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its HYPER-H23-1 phase 1b hypertension clinical trial. The submission follows a successful pre-IND meeting with the FDA, an integral step in the IND’s development and filing (https://ibn.fm/eICGt).

Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” this study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) and specifically DehydraTECH-CBD in hypertensive patients. Secondary objectives will also include efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing.

The IND submission was initially set for the end of August 2023 but was delayed by the overdue delivery of required analytical and stability information from one of Lexaria’s core ingredient suppliers. However, the company has since made tremendous progress and looks to commence with its HYPER-H23-1 clinical trial as soon as possible following IND effectiveness, subject to certain conditions, including funding.

Lexaria is optimistic about the study and looks to build on the success of its previous studies that date back to 2018. So far, the company has sponsored five investigator-initiated human clinical studies of its DehydraTECH-CBD in an aggregate total of 134 people and has not recorded a single adverse event. Positive results from these studies included significant reductions in resting blood pressure over both acute and multi-week dosing regimens alone and, in some cases, complementary to standard-of-care medications. These results suggested that DehydraTECH-CBD has the potential to have broad therapeutic utility, and that is something Lexaria is looking to explore more in its HYPER-H23-1 clinical study.

This submission affirms Lexaria’s commitment to creating shareholder value. It also points to its goal to fulfill the promises made to its shareholders, as detailed in its roadmap for the 2024 calendar year. For Chris Bunka, Lexaria’s CEO, this marks a significant milestone in line with his pledge to do all he can to “turn 2024 into the year that Lexaria leaps forward.”

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• GEMXX expects the growing demand for Ammolite, coupled with the positive outlook for gold prices, to support significant growth over the next 24 months
• Last year, GEMXX moved to complement its Ammolite operations with the purchase of gold assets in Canada
• The price of gold has held steady above US$2,000 per ounce, coming off a record-breaking 2023 when it rallied to a record-high year-end close
• The future looks promising for gold because it is projected to reach new highs in the coming months, according to GEMXX

The price of an ounce of gold rallied to a record high year-end close last year, ending 2023 at US$2,078.4, according to the World Gold Council (“WGC”). To get to this price, the value of the precious metal, which is considered a traditional safe-haven asset, had increased by 15% over 12 months, as indicated by its annual rate of return. Moreover, the average 2023 gold price of US$1,940.54/oz, also a record, was 8% higher than the average 2022 gold price, with the WGC noting that this price rally reflected strong demand (https://ibn.fm/0lSdT).

Today, the gold price has held steady above US$2,000 per ounce and is projected to reach new highs in the coming two years, according to GEMXX (OTC: GEMZ), a market-to-market gold, gemstone, and jewelry producer with global reach that owns mining resources, production facilities, and operating assets. GEMXX used this sustained upward trajectory in gold prices as well as the burgeoning demand for Ammolite jewelry to found an ambitious forecast: the company anticipates robust growth over the next 24 months (https://ibn.fm/qiMCY).

GEMXX expanded into the mining of gold last year to complement its long-standing Ammolite production. In March, GEMXX acquired a 50% interest in Crazy Horse Mining Inc. (“CHMI”), a Canadian exploration company whose assets include a 100% interest in Snow Creek and Rosella Creek gold projects located in British Columbia (https://ibn.fm/09dor). Later in September, the company announced it had signed a letter of intent to acquire a 50% interest in a property that could add up to 4 million ounces of gold to its assets (https://ibn.fm/XtyB7).

In the January 23 press release announcing the forecast of robust growth, GEMXX describes its entry into gold mining as “a new and welcomed asset to the company’s balance sheet,” with gold adding considerable support to its mine-to-market business model in “three core elements affecting long-term sustainable profitability.”

First, GEMXX says it can cut its raw material costs by about 60% by mining its own gold for its jewelry segment. The company expects these cost savings to not only reduce the cost of goods but also lead to higher and more predictable profit margins. Second, GEMXX anticipates that the mining of the gold reserves will enable it to accumulate cash reserves that will fund its future needs, thus helping the company avoid additional dilutive fundraising by issuing stock or taking debt to fund operations. “Third, investors will be able to participate in a stock based on precious metals and gemstones,” the company explains.

The press release also describes the growing demand for Ammolite jewelry, which has been driven by the rapidly growing recognition of Ammolite as a rare gemstone. Ammolite’s rarity stems from its limited availability – it is only found in southern Alberta, Canada – as well as its iridescent characteristics. GEMXX says the company has experienced additional demand throughout India and Asia, given Ammolite “appeals to a discerning clientele seeking exclusive and collectible pieces.”

With GEMXX standing out “as the leading producer of top-quality finished Ammolite, surpassing all other competitors in terms of quality and production capacity,” according to its website (https://ibn.fm/qVlIy), the company is expected to benefit significantly from the burgeoning demand.

“We are excited about the tremendous potential for growth in both the Ammolite and gold markets,” comments GEMXX President Richard Clowater. “Our commitment to quality, craftsmanship, and our ability to adapt to market dynamics position us for sustained success. We are confident we will be able to deliver strong returns to our shareholders.”

The company remains committed to expanding its product offerings, enhancing operational efficiency, and exploring strategic partnerships to maximize shareholder value while capitalizing on the positive market trends that support the realization of its strong financial outlook. Investors and stakeholders are encouraged to stay updated on GEMXX’s performance as it navigates the ever-changing jewelry and precious metals landscape.

Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/l2RhF) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com/investors.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

• Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited
• CNM-Au8(R) has demonstrated remarkable efficacy across various nervous system cell types, with its ability to target fundamental deficiencies associated with dying neurons
• Gold nanocrystals found in CNM-Au8 act as miniature mitochondria, providing neurons with much-needed ATP energy while simultaneously converting toxic reactive oxygen species into harmless compounds

Neurodegenerative diseases pose a significant challenge in healthcare, yet treatment options remain limited. Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, is working on a potentially groundbreaking nanomedicine called CNM-Au8® that aims to revolutionize the approach to addressing nervous system failure associated with these debilitating conditions.

CNM-Au8 has demonstrated remarkable efficacy across various nervous system cell types, including oligodendrocytes, motor neurons, dopaminergic neurons, hippocampal, and cortical neurons. Its effectiveness has been validated in cellular and animal models of amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease (“PD”), and multiple sclerosis (“MS”).

CNM-Au8 achieves widespread efficacy due to its ability to target fundamental deficiencies associated with dying neurons: mitochondrial dysfunction, energy metabolic deficits, and toxic levels of oxidative stress. At the heart of CNM-Au8 lie catalytically active gold particles, meticulously engineered to be about 100th the size of mitochondria. Unlike many chemically synthesized gold nanoparticles, which can exhibit toxicity, CNM-Au8’s patented electrochemical crystal growth techniques ensure high catalytic activity while minimizing harm to living organisms. These gold nanocrystals act as miniature mitochondria, providing neurons with the much-needed energetic molecule ATP while simultaneously converting toxic reactive oxygen species into harmless compounds.

The groundbreaking potential of CNM-Au8 is evident in its application across various neurodegenerative diseases. In ALS, where motor neurons suffer from mitochondrial deficits and oxidative stress, CNM-Au8 has shown promising results in prolonging survival and slowing disease progression in clinical trials. In MS, where the immune system attacks neurons’ protective myelin sheath, CNM-Au8 has demonstrated improvements in visual impairments and cognitive deficits.

The company recently discussed the VISIONARY-MS trial, which was designed to investigate the protection or improvement of neurological function in stable relapsing-remitting MS participants with chronic optic neuropathy. The trial was a Phase 2 multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of CNM-Au8 (15 mg or 30 mg daily) versus placebo over 48 weeks of double-blind treatment.

The primary outcome was low contrast letter acuity (“LCLA”) improvement, a measure of vision using a modified eye chart for people with optic neuritis caused by their Multiple Sclerosis. Global neurological improvement, measured by the modified Multiple Sclerosis Functional Composite (“mMSFC”), a comprehensive measure of vision (eyesight), cognition (thinking ability), upper extremity function (fine motor muscle movement in the hand), and walking speed assessment was the secondary outcome. The trial successfully met both primary and secondary analyses in the prespecified intent-to-treat population, which had to be modified to accommodate an early trial conclusion brought about by the COVID 19 pandemic. Nearly all participants (92%) were treated with highly effective immunomodulatory disease modifying therapies (“DMTs”) as background standard of care. This meant that the benefits observed in the treatment group were benefits that occurred above and beyond the action of the approved treatments taken by participants.

In the double-blind portion of the trial, 73 participants were randomized, with 55 of 69 eligible (80%) participants continuing in the open label long-term extension (“LTE”) of the trial. Clene announced results from the open label long-term extension in early January 2024, demonstrating that the visual and cognitive benefits observed during the double blind period translated to continued improvements in all treated individuals for the duration of the LTE (nearly 2 years from the end of the double blind period, when all participants transitioned to active drug) (https://ibn.fm/O163z).

Benjamin Greenberg, M.D., Head of Medicine at Clene said that despite advances in immunotherapies for MS, there is a significant unmet need for treatments to prevent neurodegeneration and create opportunities for clinical improvement, and that years have been spent investigating neuroprotective therapies for multiple sclerosis and other neurodegenerative diseases.

“These data continue to build a strong case in favor of pursuing CNM-Au8 in upcoming Phase 3 studies. Clinically significant improvement is rarely seen in MS patients and this trial provides evidence of CNM-Au8’s potential to improve function in this population,” said Dr. Greenberg. “Clene is currently reviewing these data with prospective pharmaceutical partners interested in MS.”

These encouraging outcomes position CNM-Au8 as a frontrunner in neurodegenerative disease treatment. As we look forward to 2024, all eyes are on Clene Nanomedicine’s innovative drug, poised to deliver further breakthroughs in the fight against these devastating conditions.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

Sustain SoCal invites regional leaders, regulatory authorities, individuals, and entities in the food and agriculture spectrum, to gather at the Sustainable Agriculture and Food Systems Event on February 20, 2024, and share their journeys, achievements, failures, and shortfalls in the existing system. With seven years in the agricultural space, the event will be attended by top industry leaders, entrepreneurs, and investors in Southern California.

For companies looking to maximize their visibility in a crowd of agriculture and food leaders, this Sustain SoCal event offers the perfect avenue. A variety of packages are available to fit every company’s needs that would offer them maximum exposure.

The expert panel of speakers includes veteran leaders and top executives in the agriculture and food fields who have years of experience and knowledge that they will share. They will also discuss the increasing needs, challenges, and growth opportunities. Attendees can put forth their queries and participate in the discussions of vital topics in the changing agriculture and food industry.

The speaker sessions, meetings, and discussion panels held at The Sustainable Agriculture and Food Event will provide the key to arriving at vital solutions for Southern California’s growing agriculture and food requirements and sustainability issues. Sustain SoCal conducts conferences that are huge networking opportunities to establish long-term business connections. The discussions and decisions made at the conference will positively impact the food and agriculture spectrum. Applications for speakers and sponsorships are welcome.

To know more, please visit https://ibn.fm/XPKZX